Axsome Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. 

CEO
Herriott Tabuteau
CEOHerriott Tabuteau
Employees
683
Employees683
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2012
Founded2012
Employees
683
Employees683

AXSM Key Statistics

Market cap
9.47B
Market cap9.47B
Price-Earnings ratio
-39.84
Price-Earnings ratio-39.84
Dividend yield
Dividend yield
Average volume
606.65K
Average volume606.65K
High today
$187.18
High today$187.18
Low today
$181.02
Low today$181.02
Open price
$184.12
Open price$184.12
Volume
371.64K
Volume371.64K
52 Week high
$191.50
52 Week high$191.50
52 Week low
$86.99
52 Week low$86.99

Stock Snapshot

As of today, Axsome Therapeutics(AXSM) shares are valued at $186.03. The company's market cap stands at 9.47B, with a P/E ratio of -39.84.

On 2026-02-11, Axsome Therapeutics(AXSM) stock moved within a range of $181.02 to $187.18. With shares now at $186.03, the stock is trading +2.8% above its intraday low and -0.6% below the session's peak.

Trading volume for Axsome Therapeutics(AXSM) stock has reached 371.64K, versus its average volume of 606.65K.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $191.50 and a low of $86.99.

Over the past 52 weeks, Axsome Therapeutics(AXSM) stock has traded between a high of $191.50 and a low of $86.99.

AXSM News

Simply Wall St 6d
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics

In recent months, Axsome Therapeutics reported interim unaudited 2025 results pointing to strong product revenue growth, while its lead drug Auvelity secured pr...

Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.